Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivoceranib in Metastatic Thymic Epithelial Tumor
NCT06200233Phase 2Not yet recruiting
- Sponsor
- Samsung Medical Center
- Start
- May 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in thymic epithelial tumor (TET), sponsored by Samsung Medical Center. Planned start May 2024; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
thymic epithelial tumor (TET)
Beyond the preview
Go deeper on NCT06200233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06200233.